Welcome to LookChem.com Sign In|Join Free

CAS

  • or
3-HYDROXY-6H-DIBENZO[B,D]PYRAN-6-ONE is a chemical compound belonging to the class of dibenzopyrans, which are organic compounds with a fused six-membered pyran ring and a seven-membered dibenzopyran core. 3-HYDROXY-6H-DIBENZO[B,D]PYRAN-6-ONE is characterized by the presence of a hydroxyl group at the 3-position, which may contribute to its potential applications in various fields.

1139-83-9 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1139-83-9 Structure
  • Basic information

    1. Product Name: 3-HYDROXY-6H-DIBENZO[B,D]PYRAN-6-ONE
    2. Synonyms: AURORA 226;3-HYDROXY-6H-DIBENZO[B,D]PYRAN-6-ONE;AKOS BBS-00008028;Urolithin B;3-Hydroxy-6H-benzo[c]chromen-6-one AldrichCPR;3-hydroxy-6-benzo[c]chromenone;3-Hydroxy-benzo[c]chromen-6-one;3-hydroxybenzo[c]chromen-6-one
    3. CAS NO:1139-83-9
    4. Molecular Formula: C13H8O3
    5. Molecular Weight: 212.2
    6. EINECS: N/A
    7. Product Categories: HR140136
    8. Mol File: 1139-83-9.mol
  • Chemical Properties

    1. Melting Point: 247 °C
    2. Boiling Point: 432.6°C at 760 mmHg
    3. Flash Point: 196.6°C
    4. Appearance: white to beige/
    5. Density: 1.395g/cm3
    6. Vapor Pressure: 4.34E-08mmHg at 25°C
    7. Refractive Index: 1.679
    8. Storage Temp.: 2-8°C
    9. Solubility: DMSO: soluble5mg/mL, clear (warmed)
    10. PKA: 9.03±0.20(Predicted)
    11. Stability: Hygroscopic
    12. CAS DataBase Reference: 3-HYDROXY-6H-DIBENZO[B,D]PYRAN-6-ONE(CAS DataBase Reference)
    13. NIST Chemistry Reference: 3-HYDROXY-6H-DIBENZO[B,D]PYRAN-6-ONE(1139-83-9)
    14. EPA Substance Registry System: 3-HYDROXY-6H-DIBENZO[B,D]PYRAN-6-ONE(1139-83-9)
  • Safety Data

    1. Hazard Codes: Xn
    2. Statements: 22
    3. Safety Statements: N/A
    4. WGK Germany: 3
    5. RTECS:
    6. HazardClass: IRRITANT
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1139-83-9(Hazardous Substances Data)

1139-83-9 Usage

Uses

Used in Pharmaceutical Industry:
3-HYDROXY-6H-DIBENZO[B,D]PYRAN-6-ONE is used as a pharmaceutical compound for its potential therapeutic properties. The hydroxyl group at the 3-position may allow for further chemical modifications, enabling the development of new drugs with specific targeting and activity profiles.
Used in Chemical Synthesis:
3-HYDROXY-6H-DIBENZO[B,D]PYRAN-6-ONE can be used as a synthetic intermediate in the production of various chemical compounds, including those with potential applications in the pharmaceutical, agrochemical, and materials science industries.
Used in Antioxidant Applications:
As an intestinal microbial metabolite of ellagitannis, 3-HYDROXY-6H-DIBENZO[B,D]PYRAN-6-ONE, also known as Urolithin B, exhibits potent antioxidant and pro-oxidant activities depending on the assay system and conditions. This dual activity makes it a promising candidate for the development of novel antioxidant therapies, particularly in the context of oxidative stress-related diseases.
Used in Hormonal Regulation:
Urolithin B can also display estrogenic and/or antiestrogenic activity, making it a potential candidate for the development of drugs targeting hormonal imbalances and related conditions, such as menopausal symptoms, hormone-sensitive cancers, and endocrine disorders.

Biochem/physiol Actions

Urolithin B is a natural product with antiproliferative and antioxidant activity. Urolithin B is formed by metabolism from polyphenols found in some nuts and fruits, particularly pomegranates. Urolithin B has been shown to cross the blood brain barrier, and may have neuroprotective effects against Alzheimer′s Disease.

Check Digit Verification of cas no

The CAS Registry Mumber 1139-83-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,1,3 and 9 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1139-83:
(6*1)+(5*1)+(4*3)+(3*9)+(2*8)+(1*3)=69
69 % 10 = 9
So 1139-83-9 is a valid CAS Registry Number.
InChI:InChI=1/C13H8O3/c14-8-5-6-10-9-3-1-2-4-11(9)13(15)16-12(10)7-8/h1-7,14H

1139-83-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name Urolithin B

1.2 Other means of identification

Product number -
Other names Uro-B

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1139-83-9 SDS

1139-83-9Relevant articles and documents

Design, synthesis, and biological evaluation of novel 6h-benzo[c]chromen-6-one derivatives as potential phosphodiesterase ii inhibitors

Tang, Long,Jiang, Jianchun,Song, Guoqiang,Wang, Yajing,Zhuang, Ziheng,Tan, Ying,Xia, Yan,Huang, Xianfeng,Feng, Xiaoqing

, (2021/05/29)

Urolithins (hydroxylated 6H-benzo[c]chromen-6-ones) are the main bioavailable metabolites of ellagic acid (EA), which was shown to be a cognitive enhancer in the treatment of neurodegenerative diseases. As part of this research, a series of alkoxylated 6H-benzo[c]chromen-6-one derivatives were designed and synthesized. Furthermore, their biological activities were evaluated as potential PDE2 inhibitors, and the alkoxylated 6H-benzo[c]chromen-6-one derivative 1f was found to have the optimal inhibitory potential (IC50: 3.67 ± 0.47 μM). It also exhibited comparable activity in comparison to that of BAY 60-7550 in vitro cell level studies.

Urolithin and reduced urolithin derivatives as potent inhibitors of tyrosinase and melanogenesis: Importance of the 4-substituted resorcinol moiety

Lee, Sanggwon,Choi, Heejeong,Park, Yujin,Jung, Hee Jin,Ullah, Sultan,Choi, Inkyu,Kang, Dongwan,Park, Chaeun,Ryu, Il Young,Jeong, Yeongmu,Hwang, Yeji,Hong, Sojeong,Chun, Pusoon,Moon, Hyung Ryong

, (2021/05/29)

We previously reported (E)-β-phenyl-α,β-unsaturated carbonyl scaffold ((E)-PUSC) played an important role in showing high tyrosinase inhibitory activity and that derivatives with a 4-substituted resorcinol moiety as the β-phenyl group of the scaffold resulted in the greatest tyrosi-nase inhibitory activity. To examine whether the 4-substituted resorcinol moiety could impart tyro-sinase inhibitory activity in the absence of the α,β-unsaturated carbonyl moiety of the (E)-PUSC scaffold, 10 urolithin derivatives were synthesized. To obtain more candidate samples, the lactone ring in synthesized urolithins was reduced to produce nine reduced urolithins. Compounds 1c (IC50 = 18.09 ± 0.25 μM), 1h (IC50 = 4.14 ± 0.10 μM), and 2a (IC50 = 15.69 ± 0.40 μM) had greater mushroom tyrosinase-inhibitory activities than kojic acid (KA) (IC50 = 48.62 ± 3.38 μM). The SAR results suggest that the 4-substituted resorcinol motif makes an important contribution to tyrosinase inhibition. To investigate whether these compounds bind to human tyrosinase, a human tyrosinase homology model was developed. Docking simulations with mushroom and human tyrosinases showed that 1c, 1h, and 2a bind to the active site of both tyrosinases with higher binding affinities than KA. Pharmacophore analyses showed that two hydroxyl groups of the 4-substituted resorcinol entity act as hydrogen bond donors in both mushroom and human tyrosinases. Kinetic analyses indicated that these compounds were all competitive inhibitors. Compound 2a inhibited cellular tyrosinase activity and melanogenesis in α-MSH plus IBMX-stimulated B16F10 melanoma cells more strongly than KA. These results suggest that 2a is a promising candidate for the treatment of skin pigment disorders, and show the 4-substituted resorcinol entity importantly contributes to tyrosinase inhi-bition.

Urolithin compound, preparation method, pharmaceutical composition and application

-

Paragraph 0066-0075, (2021/09/04)

The invention belongs to the field of medicinal chemistry, and particularly relates to a urolithin compound, a preparation method, a pharmaceutical composition and application. The urolithin compound is a compound as shown in a general formula I or an optical isomer, an enantiomer, a diastereomer, a raceme or a raceme mixture of the compound, or a pharmaceutically acceptable salt of the compound. The urolithin compound provided by the invention has good PDE2 inhibitory activity, the enzymatic level IC50 reaches 3.67 [mu] M, and the urolithin compound can be used for treating central nervous system diseases and brain neurodegenerative process diseases, and can be used as an active component to prepare drugs for inhibiting PDE2 activity.

Design, synthesis, and biological evaluation of new urolithin amides as multitarget agents against Alzheimer's disease

Shukur, Karar T.,Ercetin, Tugba,Luise, Chiara,Sippl, Wolfgang,Sirkecioglu, Okan,Ulgen, Mert,Coskun, Goknil P.,Yarim, Mine,Gazi, Mustafa,Gulcan, Hayrettin O.

, (2021/02/01)

A series of urolithin amide (i.e., URO-4–URO-10 and THU-4–THU-10) derivatives was designed and synthesized, and their chemical structures were confirmed with spectroscopic techniques and elemental analysis. The title compounds and synthesis intermediates

3-Hydroxy-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one and 3-hydroxy-6H-benzo[c] chromen-6-one act as on-off selective fluorescent sensors for Iron (III) under in vitro and ex vivo conditions

FALLAH, Amirhossein,GüLCAN, Hayrettin Ozan,GAZI, Mustafa,KALKAN, Rasime,SHUKUR, Karar,TERALI, Kerem

, p. 858 - 867 (2021/07/26)

Regarding the abundant use of metals for different purposes, it becomes more critical from various scientific and technological perspectives to discover novel agents as selective probes for the detection of specific metals. In our previous studies, we have shown that aqueous solutions of natural urolithins (i.e., hydroxyl-substituted benzo[c]chromen-6-one derivatives) are selective Iron (III) sensors in fluorescence assays. In this study, we have extrapolated these findings to another coumarine compound (i.e., 3-Hydroxy-7,8,9,10- tetrahydro-6H-benzo[c]chromen-6-one) and compared the selective metal binding properties with Urolithin B (i.e., 3-Hydroxy-6H-benzo[c]chromen-6-one). Following the synthesis and structure identification studies, the fluorometric studies pointed out that the lactam group in the structure still persists to be the important scaffold for maintaining selective on-off sensor capacity that renders the compound a selective Iron (III) binding probe. Moreover, for the first time, fluorescence cellular imaging studies concomitant to cytotoxicity assays with the title compounds were also performed and the results displayed the cell-penetrative, safe, and fluorescent detectable characteristics of the compounds in neuroblastoma and glioblastoma cells through servings as intracellular Iron (III) on-off sensors.

Facile preparation of 3,4-benzocoumarins from 2-arylbenzoic acids with NCS and NAI

Nakamura, Momoko,Togo, Hideo

, (2020/09/15)

– Treatment of 2-arylbenzoic acids with N-chlorosuccinimide (NCS) and NaI at 70 °C under fluorescent lighting condition gave the corresponding 3,4-benzocoumarins in good yields under transition-metal-free condition. It was found that the reactivity of NCS

Urolithin A and B Derivatives as ON-OFF Selective Fluorescent Sensors for Iron(III)

Fallah, Amirhossein,Noshadi, Bahareh,Gazi, Mustafa,Gülcan, Hayrettin Ozan

, p. 113 - 120 (2020/01/06)

The detection and sensing of environmentally crucial metal ions has always been of great significance in various fields such as biological and environmental cycles. Our previous studies have indicated a new coumarin based lactone, Urolithin B (i.e., 3-Hydroxy[c]chromen-6-one) as a potent fluorescent probe for the selective detection of Iron (III). In order to question the extension of this application to other urolithins, we have synthesized the major urolithins that humans are exposed to through regular diet. Following the structure identifying studies, the compounds were tested in fluorescence titration to investigate their interaction with various metals. The results have indicated that each title compound is selective to interact with Iron (III) in ON-OFF mode, independent from the presence of another metal. Similar to the previous findings, the Job’s plots displaying the ratio of complex formation 3:2 UROs:Fe3+ have indicated the significance of the lactone group solely.

Synthesis, Characterization, Molecular Docking, and Biological Activities of Some Natural and Synthetic Urolithin Analogs

Noshadi, Bahareh,Ercetin, Tugba,Luise, Chiara,Yuksel, Mine Yarim,Sippl, Wolfgang,Sahin, Mustafa Fethi,Gazi, Mustafa,Gulcan, Hayrettin Ozan

, (2020/07/24)

Urolithins (that is, hydroxy substituted benzo[c]chromen-6-one derivatives) are formed within the gastrointestinal tract following to the exposure to various ellagitannin rich diet, particularly involving pomegranate, nuts, and berries. Regarding the bioavailability deficiency of ellagitannins, the biological activities obtained through the extracts of these dietaries are attributed to the urolithin compounds, since they are bioavailable. Particularly, there are studies indicating the importance of ellagitannin-rich food for protective and alternative treatment of Alzheimer's Disease (AD). From this perspective, within this study, the major urolithins (that is, urolithins A and B), their methyl ether metabolites, as well as some synthetic urolithin analogs have been synthesized and screened for their biological activities in various enzyme inhibition (acetylcholinesterase, butyrylcholinesterase, monoamine oxidase B, cyclooxygenase 1, and cyclooxygenase 2) and antioxidant (DPPH radical scavenging) assay systems. The results pointed out the potential of urolithins to act as inhibitors on these receptors. Docking studies were also performed to investigate the possible interactions.

Is Fe-catalyzed ortho C-H Arylation of Benzamides Sensitive to Steric Hindrance and Directing Group?

Wei, Yi-Ming,Wang, Meng-Fei,Duan, Xin-Fang

supporting information, p. 6471 - 6475 (2019/08/26)

The previously reported Fe-catalyzed ortho C-H arylation of benzamides relied on bi- or tridentate amide groups and specific iron ligands and was sensitive to steric hindrance. By using new mixed titanates, our present protocol accommodates various weakly coordinating benzamides and tolerates high steric hindrance and sensitive functional groups only under the catalysis of FeCl3 and TMEDA. A wide range of privileged condensed ring compounds can thus be facilely accessed.

1,2,3,4-Tetrahydroisoquinoline/2H-chromen-2-one conjugates as nanomolar P-glycoprotein inhibitors: Molecular determinants for affinity and selectivity over multidrug resistance associated protein 1

Rullo, Mariagrazia,Niso, Mauro,Pisani, Leonardo,Carrieri, Antonio,Colabufo, Nicola Antonio,Cellamare, Saverio,Altomare, Cosimo Damiano

, p. 433 - 444 (2018/10/31)

A series of coniugates bearing a 1,2,3,4-tetrahydroisoquinoline motif linked to substituted 7-hydroxy-2H-chromen-2-ones was synthesized and assayed through calcein-AM test in Madin-Darby Canine Kidney (MDCK) cells overexpressing P-glycoprotein (P-gp) and closely related multidrug resistance associated protein 1 (MRP1) to probe the interference with efflux mechanisms mediated by P-gp and MRP1, respectively. A number of substituents at C3 and C4 of coumarin nucleus along with differently sized and shaped spacers was enrolled to investigate the effects of focused structural modifications over affinity and selectivity. Linker length and flexibility played a key role in enhancing P-gp affinity as proved by the most potent P-gp modulator (3h, IC50 = 70 nM). A phenyl ring within the spacer (3k, 3l, 3o) and bulkier groups (Br in 3r, Ph in 3u) at coumarin C3 led to derivatives showing nanomolar activity (160 nM 50 350). Molecular docking calculations carried out on a human MDR1 homology model structure contributed to gain insights into the ligands’ binding modes. Some compounds (3d, 3h, 3l, 3r, 3t, 3u) reversed MDR thereby restoring doxorubicin cytotoxicity when co-administered with the drug into MDCK-MDR1 cells.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1139-83-9